Почетна › Hronična limfocitna leukemija › Masachuset › Boston
Kliničke studije za Hronična limfocitna leukemija u gradu Boston, MA
Jedna studija za Hronična limfocitna leukemija traži učesnike na lokaciji u gradu Boston ili u blizini. Otvorite je da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Тражи се учесникФаза 3
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Тражи се учесникФаза 2
- Boston Medical Center, Boston
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Тражи се учесникФаза 3
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Тражи се учесникФаза 1/2
- Research Site, Boston
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Тражи се учесникФаза 2Здраве особе су добродошле
- DFCI/BWH Brigham and Women's Hospital, Boston
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Тражи се учесникФаза 2
- Research Site, Boston
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Тражи се учесникФаза 3
- Beth Israel Deaconess Medical Center (Bidmc), Boston
- Dana Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Тражи се учесникФаза 1Здраве особе су добродошле
- Brigham and Women's Hospital, Boston
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Тражи се учесникФаза 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Understanding Chronic Lymphocytic Leukemia
Тражи се учесникОпсервациона студија
- Dana Farber Cancer Institute, Boston
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Тражи се учесникОпсервациона студија
- Dana-Farber Cancer Institute, Boston
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Тражи се учесникФаза 2
- Dana-Farber Cancer Institute, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Тражи се учесникФаза 1/2
- Dana Farber Cancer Institute, Boston
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Тражи се учесникФаза 3
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Тражи се учесникФаза 3
- Dana Farber Cancer Institute, Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Тражи се учесникФаза 1
- Tufts Medical Center, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Тражи се учесникФаза 1/2
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Тражи се учесникФаза 4
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Тражи се учесникФаза 2
- Massachusetts General Hospital, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Тражи се учесникОпсервациона студија
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Тражи се учесникФаза 1
- Dana Farber Cancer Institute, Boston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Тражи се учесникФаза 4
- Dana-Farber Cancer Institute, Boston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Тражи се учесникФаза 4
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
Тражи се учесникФаза 1
- Beth Israel Deaconess Medical Center, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Тражи се учесникФаза 1/2
- Dana-Farber Cancer Institute, Boston
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Тражи се учесникФаза 2
- Dana-Farber Cancer Institute /ID# 230061, Boston
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Тражи се учесникФаза 2
- Beth Israel Deaconess Medical Center, Boston
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
Тражи се учесникФаза 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Тражи се учесникФаза 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Тражи се учесникФаза 1
- Dana-Farber Cancer Institute, Boston
Studije za Hronična limfocitna leukemija u drugim gradovima
- Columbus, OH29 студија
- Durham, NC28 студија
- Washington, DC22 студија
- Seattle, WA22 студија
- Rochester, MN20 студија
- New York City, NY20 студија
- Houston, TX18 студија
- Baldwin Park, CA18 студија
- Cincinnati, OH15 студија
- Milwaukee, WI15 студија
- Chicago, IL14 студија
- Nashville, TN13 студија
Ostale studije u gradu Boston
- Рак дојке110 студија
- Рак (све врсте)90 студија
- Немалоклетни карцином плућа87 студија
- Рак плућа63 студија
- Колоректални карцином62 студија
- Рак јајника62 студија
- Метастатски карцином61 студија
- Рак простате56 студија
- Карцином ендометријума51 студија
- Депресија50 студија
- Затајење срца46 студија
- Многи мијелом45 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.